» Articles » PMID: 33375151

Advances in Oral Subunit Vaccine Design

Overview
Date 2020 Dec 30
PMID 33375151
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Many pathogens invade the host at the intestinal surface. To protect against these enteropathogens, the induction of intestinal secretory IgA (SIgA) responses is paramount. While systemic vaccination provides strong systemic immune responses, oral vaccination is the most efficient way to trigger protective SIgA responses. However, the development of oral vaccines, especially oral subunit vaccines, is challenging due to mechanisms inherent to the gut. Oral vaccines need to survive the harsh environment in the gastrointestinal tract, characterized by low pH and intestinal proteases and need to reach the gut-associated lymphoid tissues, which are protected by chemical and physical barriers that prevent efficient uptake. Furthermore, they need to surmount default tolerogenic responses present in the gut, resulting in suppression of immunity or tolerance. Several strategies have been developed to tackle these hurdles, such as delivery systems that protect vaccine antigens from degradation, strong mucosal adjuvants that induce robust immune responses and targeting approaches that aim to selectively deliver vaccine antigens towards specific immune cell populations. In this review, we discuss recent advances in oral vaccine design to enable the induction of robust gut immunity and highlight that the development of next generation oral subunit vaccines will require approaches that combines these solutions.

Citing Articles

Pivotal role of virulence genes in pathogenicity and vaccine development.

Elbehiry A, Marzouk E, Abalkhail A, Sindi W, Alzahrani Y, Alhifani S Front Med (Lausanne). 2025; 11():1523991.

PMID: 39850097 PMC: 11756510. DOI: 10.3389/fmed.2024.1523991.


A Polysaccharide-Based Oral-Vaccine Delivery System and Adjuvant for the Influenza Virus Vaccine.

Valiveti C, Rajput M, Thakur N, Momin T, Bhowmik M, Tummala H Vaccines (Basel). 2024; 12(10).

PMID: 39460287 PMC: 11511251. DOI: 10.3390/vaccines12101121.


Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease.

Zheng B, Wang L, Yi Y, Yin J, Liang A Asian J Pharm Sci. 2024; 19(4):100943.

PMID: 39246510 PMC: 11375318. DOI: 10.1016/j.ajps.2024.100943.


Recent development of oral vaccines (Review).

Liu Y, Lam D, Luan M, Zheng W, Ai H Exp Ther Med. 2024; 27(5):223.

PMID: 38590568 PMC: 11000446. DOI: 10.3892/etm.2024.12511.


Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal immunity against H. pylori infection.

Zhang F, Ni L, Zhang Z, Luo X, Wang X, Zhou W Microb Cell Fact. 2024; 23(1):61.

PMID: 38402145 PMC: 10893618. DOI: 10.1186/s12934-024-02321-4.


References
1.
Kawane K, Motani K, Nagata S . DNA degradation and its defects. Cold Spring Harb Perspect Biol. 2014; 6(6). PMC: 4031964. DOI: 10.1101/cshperspect.a016394. View

2.
Barouch D . Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 2010; 5(5):386-90. PMC: 2967414. DOI: 10.1097/COH.0b013e32833cfe4c. View

3.
Upham J, Sehmi R, Hayes L, Howie K, Lundahl J, Denburg J . Retinoic acid modulates IL-5 receptor expression and selectively inhibits eosinophil-basophil differentiation of hemopoietic progenitor cells. J Allergy Clin Immunol. 2002; 109(2):307-13. DOI: 10.1067/mai.2002.121527. View

4.
Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U . Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh. EBioMedicine. 2016; 2(11):1759-66. PMC: 4740306. DOI: 10.1016/j.ebiom.2015.09.036. View

5.
Xiao S, Jin H, Korn T, Liu S, Oukka M, Lim B . Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol. 2008; 181(4):2277-84. PMC: 2722959. DOI: 10.4049/jimmunol.181.4.2277. View